Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest update is out from Revance Therapeutics (RVNC).
Revance Therapeutics, Inc. has extended its agreement with Ajinomoto Bio-Pharma Services until December 31, 2027, for manufacturing services related to DAXXIFY® at their San Diego facility, with updated terms regarding product conformity and delay remedies. Additionally, the company’s President, Mr. Sjuts, will step down, receiving a severance package, which includes 18 months of his base salary and health benefits, and will remain as a consultant for a year to ensure a smooth transition and allow his equity awards to continue vesting.
For an in-depth examination of RVNC stock, go to TipRanks’ Stock Analysis page.
